^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-813160

    i
    Other names: BMS-813160, BMS 813160 , BMS813160
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    CCR5 receptor antagonist, CCR2 receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=332, Completed, Bristol-Myers Squibb | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium • BMS-813160
    2ms
    Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
    P1/2, N=46, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Sep 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    9ms
    Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer. (PubMed, Clin Cancer Res)
    Neoadjuvant BMS-813160/nivolumab/GnP was well tolerated and appears to achieve comparable ORR and resectability to historical data, however with prolonged PFS and OS in LA-PDAC patients, warranting a larger phase II study with a more efficacious CCR2-targeted therapeutic.
    Journal • PD(L)-1 Biomarker
    |
    CCR2 (C-C Motif Chemokine Receptor 2)
    |
    Opdivo (nivolumab) • gemcitabine • albumin-bound paclitaxel • BMS-813160
    11ms
    GCO 19-1754: Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Completed --> Active, not recruiting | Trial completion date: Nov 2023 --> Dec 2025 | Trial primary completion date: Nov 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • BMS-813160 • BMS-986253
    12ms
    Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
    P1/2, N=46, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Completed | N=30 --> 46 | Trial completion date: Dec 2024 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Sep 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    over1year
    BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
    P1/2, N=40, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • gemcitabine • albumin-bound paclitaxel • BMS-813160
    over1year
    GCO 19-1754: Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2, N=48, Completed, Icahn School of Medicine at Mount Sinai | N=36 --> 48 | Trial completion date: Sep 2024 --> Nov 2023 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date
    |
    Opdivo (nivolumab) • BMS-813160 • BMS-986253
    almost2years
    Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    over2years
    A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=332, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium • BMS-813160
    almost3years
    Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)